Daniel Palmacci

Investing capital in capacity expansion when a drug is early in development is challenging. There are new manufacturing models that reduce risk and add value to your decisions through a concept called optionality Balancing options and critically evaluated risk against probability of success in to-build decisions Introducing a new biomanufacturing solution that leverages manufacturing ecosystems to reduce the need to build infrastructure Effectively transfer non-value added work from the manufacturing site to service providers with this new manufacturing model — Daniel Palmacci has nearly 20 years of leadership experience in Biologics in the area of manufacturing, technical development, supply chain,…